

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1 Name and Address of Company

HYTN Innovations Inc. (the “Company”)
12 East 4th Avenue
Vancouver, BC
Canada V5T 1E8

Item 2 Date of Material Change

October 17, 2022

Item 3 News Release

The Company disseminated a news release announcing the material change described herein through the news dissemination services of Globe Newswire on October 17, 2022, and a copy was subsequently filed on SEDAR.

Item 4 Summary of Material Change

The Company announced that its wholly owned subsidiary, HYTN Cannabis Inc., has been awarded a Controlled Drugs and Substances Dealer’s Licence by Health Canada allowing for the sale, possession, production, assembly and transportation of psilocybin, a naturally occurring psychedelic prodrug compound produced by a number of fungi.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

The Company announced that its wholly owned subsidiary, HYTN Cannabis Inc., has been awarded a Controlled Drugs and Substances Dealer’s Licence (the “**License**”) by Health Canada allowing for the sale, possession, production, assembly and transportation of psilocybin, a naturally occurring psychedelic prodrug compound produced by a number of fungi.

This announcement follows several license achievements including a Standard Processing License and its Amendment for Sale, a Cannabis Research License, a Standard Cultivation License, and a Medical Sales License (with possession). The Company notes that this achievement has not been widely accomplished by Canadian cannabis licence holders and demonstrates the Company’s ability to work with regulators to enhance licenced activities within its purpose-built ISO 9001:2015 accredited Kelowna production facility.

Under the License, the Company may possess up to 300 grams of psilocybin or its equivalent in biomass at any time and can sell or transfer extracted material or final drug products to other licenced dealers or authorized markets outside of Canada. HYTN intends to begin researching and developing psilocybin-based products that complement its current offerings of cannabis beverages and edibles.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on Subsection 7.1(2) of National Instrument 51-102

This report is not being filed on a confidential basis.

Item 7 Omitted Information

There are no significant facts required to be disclosed herein which have been omitted.

Item 8 Executive Officer

For further information, please contact Elliot McKerr, Chief Executive Officer and Director of the Company, at 1-866-590-9289.

Item 9 Date of Report

October 17, 2022